Publikationen 2010

  • Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis. Doerck S, Göbel K, Weise G, Schneider-Hohendorf T, Reinhardt M, Hauff P, Schwab N, Linker R, Mäurer M, Meuth SG, Wiendl H. PLoS One. 2010; 15;5(11):e15478.

 

  • Evolving expectations around early management of multiple sclerosis. Gold R, Wolinsky JS, Amato MP, Comi G. Ther Adv Neurol Disord. 2010 Nov;3(6):351-67.

 

  • Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosis. Chan A, Decard BF, Franke C, Grummel V, Zhou D, Schottstedt V, Toyka KV, Hemmer B, Gold R. Mult Scler. 2010 Oct;16(10):1189-92.

 

  • The Impact of Adherence with Interferons in the Treatment of Multiple Sclerosis. Steinberg SC, Faris RF, Chang CF, Chan A, Tankersley MA. Clinical Drug Investigation, 2010;30:1-14.

 

  • Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Linker RA, Lee DH, Demir S, Wiese S, Kruse N, Siglienti I, Gerhardt E, Neumann H, Sendtner M, Lühder F, Gold R. Brain. 2010 Aug;133(Pt 8):2248-63.

 

  • Genetic polymorphism at codon 129 of the prion protein gene is not associated with primary progressive multiple sclerosis. Stüve O, Wang J, Chan A, Hemmer B, Cepok S, Nessler S, Zipp F, Goldman MD, Meuth SG, Korth C, Lambracht-Washington D.  Archives of Neurology, 2010;67:1307-1315 

 

  • The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation. Haghikia A, Gold R. Am J Pathol. 2010 Jun;176(6):2599-601.

 

  • Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease. Arning L, Haghikia A, Taherzadeh-Fard E, Saft C, Andrich J, Pula B, Höxtermann S, Wieczorek S, Akkad DA, Perrech M, Gold R, Epplen JT, Chan A. J Mol Med. 2010 Apr;88(4):431-6.

 

  • Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Berger JR, Centonze D, Comi G, Confavreux C, Cutter G, Giovannoni G, Gold R, Hartung HP, Lublin F, Miravalle A, Montalban X, O'Connor P, Olsson T, Polman CH, Stuve O, Wolinsky JS, Ziemssen T. Ann Neurol. 2010 Sep;68(3):409-11.

 

  • Glucocorticoid effects on endothelial barrier function in the murine brain endothelial cell line cEND incubated with sera from patients with multiple sclerosis. Blecharz KG, Haghikia A, Stasiolek M, Kruse N, Drenckhahn D, Gold R, Roewer N, Chan A, Förster CY. Mult Scler. 2010 Mar;16(3):293-302.

 

  • Mitoxantron-assoziierte akute Leukämie bei Multipler Sklerose: Fallbericht und praktisches Vorgehen bei unklaren Zytopenien. Meyer C, Ansorge N, Siglienti I, Salmen S, Stroet A, Nückel H, Dührsen U, Ritter P, Schmidt WE, Gold R, Chan A. Nervenarzt. 2010; 8:1483-1489.